1. Home
  2. CELC vs SD Comparison

CELC vs SD Comparison

Compare CELC & SD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • SD
  • Stock Information
  • Founded
  • CELC 2011
  • SD 2006
  • Country
  • CELC United States
  • SD United States
  • Employees
  • CELC N/A
  • SD N/A
  • Industry
  • CELC Medical Specialities
  • SD Oil & Gas Production
  • Sector
  • CELC Health Care
  • SD Energy
  • Exchange
  • CELC Nasdaq
  • SD Nasdaq
  • Market Cap
  • CELC 440.0M
  • SD 380.4M
  • IPO Year
  • CELC 2017
  • SD 2007
  • Fundamental
  • Price
  • CELC $13.77
  • SD $10.33
  • Analyst Decision
  • CELC Strong Buy
  • SD
  • Analyst Count
  • CELC 6
  • SD 0
  • Target Price
  • CELC $30.67
  • SD N/A
  • AVG Volume (30 Days)
  • CELC 245.9K
  • SD 297.5K
  • Earning Date
  • CELC 08-13-2025
  • SD 08-06-2025
  • Dividend Yield
  • CELC N/A
  • SD 4.19%
  • EPS Growth
  • CELC N/A
  • SD 33.83
  • EPS
  • CELC N/A
  • SD 1.74
  • Revenue
  • CELC N/A
  • SD $137,611,000.00
  • Revenue This Year
  • CELC N/A
  • SD $37.50
  • Revenue Next Year
  • CELC N/A
  • SD $5.17
  • P/E Ratio
  • CELC N/A
  • SD $6.04
  • Revenue Growth
  • CELC N/A
  • SD 1.35
  • 52 Week Low
  • CELC $7.58
  • SD $8.81
  • 52 Week High
  • CELC $19.77
  • SD $13.93
  • Technical
  • Relative Strength Index (RSI)
  • CELC 59.12
  • SD 43.69
  • Support Level
  • CELC $13.47
  • SD $10.08
  • Resistance Level
  • CELC $14.57
  • SD $10.40
  • Average True Range (ATR)
  • CELC 0.65
  • SD 0.26
  • MACD
  • CELC -0.04
  • SD -0.05
  • Stochastic Oscillator
  • CELC 36.65
  • SD 21.93

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About SD SandRidge Energy Inc.

SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.

Share on Social Networks: